Aché Laboratórios Farmacêuticos SA has synthesized compounds acting as β2-adrenoceptor (ADRB2) agonists and muscarinic M3 receptor antagonists reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and rhinitis.
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest further in generative AI and automated laboratories.
Acute lung injury (ALI) is a severe condition marked by uncontrolled lung inflammation and tissue damage, often leading to respiratory failure. Excessive immune activation recruits neutrophils that release pro-inflammatory cytokines, including IL‑6 and TNF‑α, while generating reactive oxygen species (ROS) that damage DNA and trigger cell death. Thus, controlling inflammation and limiting ROS are key strategies to prevent ALI.
